Protara Therapeutics (TARA) Gains from Investment Securities (2013 - 2026)

Protara Therapeutics' Gains from Investment Securities history runs 14 years deep, the most recent figure standing at $7000.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 99.86% year-over-year to $7000.0; the TTM figure through Mar 2026 stood at $7000.0 (down 99.86% YoY), while the FY2025 annual figure was $1.7 million, down 70.15% from the prior year.
• Gains from Investment Securities was $7000.0 for Q1 2026 at Protara Therapeutics, down from $1.7 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $5.7 million in Q4 2024 to a low of $3933.0 in Q2 2023.
• Historically, Gains from Investment Securities has averaged $1.9 million across 5 years, with a median of $1.7 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Gains from Investment Securities soared 38038.83% in 2024, then plunged 99.86% in 2026.
• A 5-year view of Gains from Investment Securities shows it stood at $1.8 million in 2022, then jumped by 58.63% to $2.9 million in 2023, then surged by 96.33% to $5.7 million in 2024, then plunged by 70.15% to $1.7 million in 2025, then plunged by 99.59% to $7000.0 in 2026.
• The last three Gains from Investment Securities figures came in at $7000.0 (Q1 2026), $1.7 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.